Oxford, United Kingdom

Scancell is a clinical-stage immuno-oncology specialist that is developing two innovative and flexible antibody (AvidiMab and GlyMab) and two therapeutic vaccine platforms (Moditope and ImmunoBody) with the potential to treat various cancers.

Investment Perspective

Scancell is a clinical stage immunology specialist. It has two promising oncology vaccine platforms, Moditope and ImmunoBody, and two antibody technologies, GlyMab (anti-glycans) and AvidiMab, with the potential to treat many solid cancers, either as monotherapy or in combination. Modi-1, the first Moditope programme, is progressing in a Phase I/II trial targeting hard-to-treat tumours with further efficacy data due 2024. The lead ImmunoBody programme, currently SCIB1, is in a Phase II study in metastatic melanoma, with a transition to the next-generation iSCIB1+ expected later this year. The broad acting GlyMab antibodies are generating exciting preclinical data, and a first partnering deal with Genmab is already in place and further deals are possible. AvidiMab technology will be increasingly employed to enhance avidity and potency. Our risk adjusted NPV valuation for Scancell is currently £300.1m, or 36.7p/share, with significant upside from multiple upcoming catalysts.

Market information

SymbolPrimary exchanges


Business update and FY23 results
Lighthouse | 31 Oct 2023
SCIB1 SCOPE study shows a striking 82% ORR
Lighthouse | 19 Sep 2023
Upcoming SCIB1 data could provide first proof of concept
Update | 05 Sep 2023

Recent News

Update on SCOPE trial
28 Nov 2023
Presentation of data from first stage of Phase II SCOPE trial at 38th Annual SITC meeting
01 Nov 2023
Results for the year ended 30 April 2023
31 Oct 2023
Presentation at World Vaccine Congress Europe
18 Oct 2023